Indication 1: Androgenetic alopecia
Indication 2: androgen-dependent Prostate cancer


Around 50% of men and 30% of women experience some degree of androgenetic alopecia by the age of 50. AR suppression reduces the activity of dihydrotestosterone (DHT), which binds to androgen receptors in hair follicles and leads to hair thinning and eventual hair loss.

Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of cancer-related death worldwide. Around 80–90% of prostate cancers are androgen-dependent. We are developing therapy for suppression of the AR gene expression to slow cancer growth and progression.

Indication: Psoriasis

Description:
Topical gene therapy for downregulating the NFKBIZ (NFKB inhibitor zeta) gene expression to reduce inflammation and keratinocyte proliferation in psoriatic skin.

Around 2-3% of the global population is affected by psoriasis, meaning approximately 125 to 180 million people live with this condition. NFKBIZ is a key participant in skin inflammation pathways, and its expression is elevated in psoriatic skin. Downregulation of the NFKBIZ signaling reduces pro-inflammatory cytokine levels and alleviates psoriasis symptoms.

Indication: various cancers

AXL is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain.

AXL is widely expressed in many organs:
• Macrophages
• Endothelial cells
• Heart
• Liver and skeletal muscle

AXL signaling controls:
• EMT
• Survival
• Motility
• Invasion
• Metastasis development.